Hematologic tumor and lymphoma

Open Access
Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma
Gaofeng Zheng, Ruyi Xu, Heng Mei, Xiaoyan Han, Donghua He, Yanling Weng, Cheng Wen, Zhuoxiao Cao and Zhen Cai

Cancer Biology & Medicine November 2025, 22 (11) 1377-1380; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0581
Open Access
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study
Keshu Zhou, Huijing Wu, Xia Zhao, Xiaohong Tan, Xiaojing Yan, Haisheng Liu, Liping Su, Yukun Lan, Jaihui Xu, Xiaohui Zhou, Yuerong Shuang and Huilai Zhang

Cancer Biology & Medicine October 2025, 22 (10) 1218-1222; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0104
Open Access
Non-essential role of S100A9 in hematopoiesis in primary MPN and MDS mouse models
Qinglin Li, Xuezhen Ma, Zhaofeng Li, Xinshu Xie, Yating Lu, Hanqi Liu, Ailing Zou, Yexin Yang, Jie Ouyang, Shuqian Xu and Yang Mei

Cancer Biology & Medicine July 2025, 22 (7) 806-811; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0185
Open Access
Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy
Yao Qi, Jia Wang, Jingyi Li and Qi Deng

Cancer Biology & Medicine June 2025, 22 (6) 644-647; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0087
Open Access
Prognostic value of peripheral eosinophil counts in patients with newly diagnosed multiple myeloma
Xu Chen, Xiaoyan Yue, Hao Jiang, Qianqian Yang, Jinwen Huang, Wenjue Pan, Xiujie Zhao, Xiufeng Yin, Panpan Wang, Liangning Hu, Xiaoli Guo, Fangfei Shao and Haowen Xiao

Cancer Biology & Medicine May 2025, 22 (5) 481-487; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0448
Open Access
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy
Hui Luo, Tongjuan Li, Fankai Meng, Zhenya Hong, Yang Cao, Gaoxiang Wang, Liang Huang and Xiaoxi Zhou

Cancer Biology & Medicine May 2025, 22 (5) 496-501; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0626
Open Access
Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma
Tianshu Yu, Xianhuo Wang, Ou Bai, Huilai Zhang and Wenbin Qian

Cancer Biology & Medicine April 2025, 22 (4) 301-321; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0538
Open Access
Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma
Yi Wang, Yuting Yan, Dandan Shan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Wenjie Xiong, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Dehui Zou and Shuhua Yi

Cancer Biology & Medicine February 2025, 22 (2) 177-189; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0200
Open Access
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine
Lina Hu, Xuanye Zhang and Shengbing Zang

Cancer Biology & Medicine September 2024, 21 (9) 754-768; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0132
Open Access
Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020
Eleonora Feletto, Qingwei Luo, Anna Kelly, Marianne Weber, David Goldsbury, Katherine Barron, Karen Canfell and Xue Qin Yu

Cancer Biology & Medicine August 2024, 21 (8) 703-711; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0177

Main menu

User menu

Search

Hematologic tumor and lymphoma

Pages

Navigate

More Information

For Authors

Journal Services